Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) have been assigned a consensus recommendation of “Hold” from the eight brokerages that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.33.

Several research analysts have recently weighed in on the stock. Chardan Capital restated a “buy” rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Tuesday, July 16th. Zacks Investment Research upgraded shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, ValuEngine downgraded shares of Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of Montreal Can boosted its stake in Arbutus Biopharma by 1.2% during the 1st quarter. Bank of Montreal Can now owns 979,124 shares of the biopharmaceutical company’s stock valued at $3,505,000 after acquiring an additional 11,520 shares during the last quarter. Norges Bank bought a new position in Arbutus Biopharma during the 4th quarter valued at $1,416,000. Geode Capital Management LLC boosted its stake in Arbutus Biopharma by 27.7% during the 4th quarter. Geode Capital Management LLC now owns 235,932 shares of the biopharmaceutical company’s stock valued at $903,000 after acquiring an additional 51,127 shares during the last quarter. Bailard Inc. boosted its stake in Arbutus Biopharma by 5.6% during the 1st quarter. Bailard Inc. now owns 228,000 shares of the biopharmaceutical company’s stock valued at $816,000 after acquiring an additional 12,000 shares during the last quarter. Finally, Alps Advisors Inc. boosted its stake in Arbutus Biopharma by 4.7% during the 1st quarter. Alps Advisors Inc. now owns 134,053 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 6,016 shares during the last quarter. Hedge funds and other institutional investors own 41.76% of the company’s stock.

ABUS opened at $1.80 on Thursday. The company has a current ratio of 12.75, a quick ratio of 12.75 and a debt-to-equity ratio of 0.06. Arbutus Biopharma has a 52-week low of $1.42 and a 52-week high of $12.60. The stock’s 50 day simple moving average is $2.01. The stock has a market capitalization of $102.33 million, a P/E ratio of -1.76 and a beta of 1.87.

Arbutus Biopharma (NASDAQ:ABUS) last released its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.16). The business had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.18 million. Arbutus Biopharma had a negative return on equity of 95.26% and a negative net margin of 1,237.92%. As a group, equities research analysts anticipate that Arbutus Biopharma will post -1.56 EPS for the current year.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. Its HBV product pipeline consists of AB-506, a capsid inhibitor that has shown improved potency and pharmacokinetics over its first generation capsid inhibitor; and AB-423, which is in pre-clinical studies.

See Also: Trading Ex-Dividend Strategy

Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.